Inflammatory mediators in the vitreal reflux of patients with diabetic macular edema
- 59 Downloads
To quantify inflammatory, growth/angiogenic, and tissue remodeling mediators in vitreal reflux (VR) in patients with diabetic macular edema (DME), as collected at first and third intravitreal anti-vascular endothelial growth factor (anti-VEGF, ranibizumab) injection.
Thirty (30) consecutive patients (type-2 diabetes mellitus) with visual impairments due to DME and undergoing the first (untreated DME) or the third (treated DME) intravitreal injection of anti-VEGF were included in the study. At the time of surgery, patients were subjected to clinical assessment and spectral domain-optical coherence tomography (SD-OCT), including central retinal thickness (CRT), macular volume, and outer nuclear layer/retinal pigment epithelial (ONL/RPE) measurements. VR sampling was performed at the time of needle removal and subjected to customized protein-array, Western blotting (WB), Ella™ microfluidic, and/or enzyme-linked immunosorbent assay (ELISA) analysis. Biostrumental and biochemical data were collected just prior to the surgery and are representative of disease state. Clinical, biostrumental, and numerous biomarkers and cytokines were statistically compared.
Decreased CRT values were detected in treated DME retinas, as compared to untreated ones (p ≤ 0.05). Differences in VEGF and other mediator expressions between treated and untreated DME were detected in VR samples. Particularly, osteopontin (p ≤ 0.05), interleukin 6 (IL6) (p ≤ 0.05), and VEGF (p ≤ 0.1) values were decreased after treatment. Significant changes were validated by WB, ELISA, and Ella™ analysis.
Overall, the biostrumental and biochemical data suggest the presence of a specific pattern of inflammation in VR after treatment. The data would suggest the presence of other mechanisms and mediators, in addition to VEGF, accountable for DME progression.
KeywordsAnti-VEGF DME Inflammation Vitreal reflux Osteopontin
The study was partially supported by the Italian Ministry of Health (RC2016), Fondazione Roma (Italy), and MaBIOS-kit Grant (AC, GE, AM; Regione Lazio; LR13/2015; FILAS-RU-2014-112).
Italian Ministry of Health and Fondazione Roma (Italy).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The study was approved by the intramural IFO/Bietti Ethics committee and conducted in accordance with the ethical standards stated in the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.
- 20.Bressler NM, Beaulieu WT, Glassman AR et al (2018) Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 136:257–269. https://doi.org/10.1001/jamaophthalmol.2017.6565 CrossRefGoogle Scholar
- 21.Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW et al (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophtalmology 117:1064–1077. https://doi.org/10.1016/j.ophtha.2010.02.031 CrossRefGoogle Scholar
- 25.Dabir SS, Das D, Nallathambi J, Mangalesh S, Yadav NK, Schouten JS (2014) Differential systemic gene expression profile in patients with diabetic macular edema: responders versus nonresponders to standard treatment. Indian J Ophthalmol 62:66–73. https://doi.org/10.4103/0301-4738.126186 CrossRefGoogle Scholar
- 33.Abu El-Asrar AM, Nawaz MI, De Hertogh G et al (2014) S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis. Mol Vis 20:1209–1224Google Scholar
- 36.Chen H, Zhang X, Liao N, Wen F (2016) Increased levels of IL-6, sIL-6R, and sgp130 in the aqueous humor and serum of patients with diabetic retinopathy. Mol Vis 22:1005–1014Google Scholar
- 40.Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P, Muthukkaruppan V (2008) Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales’ disease. Retina 28:817–824. https://doi.org/10.1097/IAE.0b013e31816576d5 CrossRefGoogle Scholar
- 42.Yoshida S, Kobayashi Y, Nakao S et al (2017) Differential association of elevated inflammatory cytokines with postoperative fibrous proliferation and neovascularization after unsuccessful vitrectomy in eyes with proliferative diabetic retinopathy. Clin Ophthalmol 11:1697–1705. https://doi.org/10.2147/OPTH.S141821 CrossRefGoogle Scholar
- 43.Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD, Prospective Complications Study Group (2005) Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes--the EURODIAB prospective complications study. Diabetologia 48:370–378. https://doi.org/10.1007/s00125-004-1628-8 CrossRefGoogle Scholar
- 45.Chen H, Wen F, Zhang X, Su SB (2012) Expression of T-helper-associated cytokines in patients with type 2 diabetes mellitus with retinopathy. Mol Vis 18:219–226Google Scholar
- 46.Jacqueminet S, Ben Abdesselam O, Chapman MJ, Nicolay N, Foglietti MJ, Grimaldi A, Beaudeux JL (2006) Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta 367:103–107. https://doi.org/10.1016/j.cca.2005.11.029 CrossRefGoogle Scholar